

# Verana Health Helps Syneos Meet Enrollment Goals in Saturated Market

**Syneos and EyePoint encountered challenges in patient recruitment** for a phase II study of patients with wet age-related macular degeneration (wet AMD). The market was saturated with several concurrent studies and many trial sites were experiencing staffing and resourcing challenges. Syneos, the contract research organization (CRO) for EyePoint, engaged Verana Health to identify and contact potentially eligible patients to boost patient recruitment. Applying patient identification and site selection services featuring Verana Trial Connect (VTC), Verana Health identified 31 active trial sites with a high number of potentially eligible patients in just five weeks.

## Challenge

- Syneos and EyePoint faced difficulties in patient recruitment for a phase II study of patients with wet age-related macular degeneration (wet AMD).
- A saturated market with several concurrent studies for this indication impeded progress.
- Many trial sites were experiencing staffing and resourcing challenges.
- Syneos, the contract research organization (CRO) for EyePoint, sought assistance to improve recruitment and enrollment.



Overcame  
Saturated  
Market in  
**5 Weeks**

## Partnering with Verana :

- **To help the study meet its goals**, Verana Health provided patient identification services to support site selection and patient pre-qualification using Verana Trial Connect (VTC).
- Verana Health applied the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and **collaborated with Syneos and Eyepoint to determine which inclusion/exclusion criteria** from the study protocol should be included.
- Using that algorithm, Verana Health identified potential practices and then **provided interested practices with access to VTC** and a curated list of their own patients eligible for the study.
- In conjunction with the practice, **Verana Health supported the site to pre-qualify participants identified in the platform**, allowing for more efficient patient recruitment efforts and reducing administrative burden on site staff.

## Results:

- **Verana Health identified potential trial sites** and screened patients for this wet AMD clinical trial in 5 weeks.
- **Verana Health identified 31 active trial sites** with a high number of potentially eligible patients.
- **Verana Health worked closely with Syneos** to be introduced to the 31 sites, providing a demo of VTC to interested sites; 15 sites were activated with VTC.
- Upon completion, **27 patients were screened for the study**.
- With support from Verana Health, **EyePoint successfully completed their enrollment goal** for the clinical trial.


### About Verana Health

Verana Health® is revolutionizing patient care and clinical research by unlocking the potential of real-world data. Verana Health has an exclusive real-world data network of 90 million de-identified patients from more than 20,000 clinicians, stemming from its exclusive data partnerships with leading medical societies. Verana Health harnesses deep expertise, secure advanced technology, and direct access to exclusive, near real-time data sources to deliver actionable quality insights that help companies make sense of the data. For more information, visit [www.veranahealth.com](http://www.veranahealth.com)

## VTC:

### Verana Trial Connect

A secure, cloud-based platform that provides physicians a curated list of their own patients eligible for the study based on protocol inclusion and exclusion criteria.



Learn how  
Verana Health can  
empower your  
clinical research: [veranahealth.com/contact](http://veranahealth.com/contact)